Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Faria M. Siddiqui"'
Autor:
Aaron N. Hata, Paul E. Hughes, Cyril H. Benes, Angela Coxon, Sean P. Brown, Kristopher A. Sarosiek, Justin F. Gainor, Christopher G. Azzoli, Anna F. Farago, Zofia Piotrowska, Lecia V. Sequist, Colleen Keyes, John H. Shin, Daniel P. Cahill, Kevin A. Raskin, Cameron D. Wright, Michael Lanuti, Lorin A. Ferris, Kristof Vajda, Diamanda Rigas, Cameron Fraser, Chendi Li, Hannah L. Archibald, Maria Gomez-Caraballo, Nicole Phan, Samantha J. Bilton, Daria Timonina, Sean Caenepeel, Faria M. Siddiqui, Varuna Nangia
BH3 mimetic drugs, which inhibit prosurvival BCL2 family proteins, have limited single-agent activity in solid tumor models. The potential of BH3 mimetics for these cancers may depend on their ability to potentiate the apoptotic response to chemother
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::70abe6bdd9a6b3e57487dfcfd1b546b5
https://doi.org/10.1158/2159-8290.c.6547298.v1
https://doi.org/10.1158/2159-8290.c.6547298.v1
Autor:
Aaron N. Hata, Paul E. Hughes, Cyril H. Benes, Angela Coxon, Sean P. Brown, Kristopher A. Sarosiek, Justin F. Gainor, Christopher G. Azzoli, Anna F. Farago, Zofia Piotrowska, Lecia V. Sequist, Colleen Keyes, John H. Shin, Daniel P. Cahill, Kevin A. Raskin, Cameron D. Wright, Michael Lanuti, Lorin A. Ferris, Kristof Vajda, Diamanda Rigas, Cameron Fraser, Chendi Li, Hannah L. Archibald, Maria Gomez-Caraballo, Nicole Phan, Samantha J. Bilton, Daria Timonina, Sean Caenepeel, Faria M. Siddiqui, Varuna Nangia
Supplementary Figure 1-5, Supplementary Tables 1-3
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9d14dcf58051aa128a6d420a7ae16b05
https://doi.org/10.1158/2159-8290.22533896.v1
https://doi.org/10.1158/2159-8290.22533896.v1
Autor:
Lorin A. Ferris, Kristof Vajda, Hannah L. Archibald, Daniel P. Cahill, Justin F. Gainor, Diamanda Rigas, Sean P. Brown, Anna F. Farago, Aaron N. Hata, Chendi Li, Cyril H. Benes, Kevin A. Raskin, Varuna Nangia, Michael Lanuti, Cameron D. Wright, John H. Shin, Kristopher A. Sarosiek, Lecia V. Sequist, Christopher G. Azzoli, Angela Coxon, Daria Timonina, Faria M. Siddiqui, Zofia Piotrowska, Paul E. Hughes, Sean Caenepeel, Cameron Fraser, Maria Gomez-Caraballo, Nicole Phan, Colleen Keyes, Samantha J. Bilton
Publikováno v:
Cancer Discovery. 8:1598-1613
BH3 mimetic drugs, which inhibit prosurvival BCL2 family proteins, have limited single-agent activity in solid tumor models. The potential of BH3 mimetics for these cancers may depend on their ability to potentiate the apoptotic response to chemother
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::162f750a90903f1f67501d3d374a8d7a
https://doi.org/10.1158/2159-8290.cd-18-0277
https://doi.org/10.1158/2159-8290.cd-18-0277
Autor:
Mandeep Banwait, Pégah Jalili, Jiachen Lin, Heidie Frisco-Cabanos, S. Oh, Nicole Phan, Lee Zou, Zofia Piotrowska, Marcello Stanzione, Daria Timonina, L.V. Sequist, Jeffrey A. Engelman, Varuna Nangia, Rémi Buisson, Faria M. Siddiqui, Rosemary Cobb, Aaron N. Hata, K. Dionne, Jaewon J. Lee, Hannah L. Archibald, Cyril H. Benes, Amanda K. Riley, Nicholas J. Dyson, Michael W. Lawlor, Cheong Xin Chan, Christopher J. Ott, H. Isozaki, A. Abbasi, Maria Gomez-Caraballo, Gad Getz, Adam Langenbucher, Samantha J. Bilton, Alice T. Shaw, Yosef E. Maruvka, Wenjia Su, Michael S. Lawrence, N. Nikpour
Acquired drug resistance to even the most effective anti-cancer targeted therapies remains an unsolved clinical problem. Although many drivers of acquired drug resistance have been identified1‒6, the underlying molecular mechanisms shaping tumor ev
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::152a1f612e569ef1a840877cfed64792
https://doi.org/10.1101/2021.01.20.426852
https://doi.org/10.1101/2021.01.20.426852
Autor:
Hannah L. Archibald, Steve Rowley, Faria M. Siddiqui, Sukhvinder Sidhu, Aaron N. Hata, Madelyn Light, Jeffrey A. Engelman, James Watters, Joon Sang Lee, Maria Gomez-Caraballo, Joonil Jung, Laurent Debussche, Ruslan I. Sadreyev, Fei Ji
Publikováno v:
Oncogene
There are currently no effective targeted therapies for KRAS mutant cancers. Therapeutic strategies that combine MEK inhibitors with agents that target apoptotic pathways may be a promising therapeutic approach. We investigated combining MEK and MDM2
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::115f96e271e86bb97406eb44fcaa7ce3
https://doi.org/10.1038/onc.2017.258
https://doi.org/10.1038/onc.2017.258
Publikováno v:
Genetics. 201:1087-1102
One challenge in modern medicine is to control epilepsies that do not respond to currently available medications. Since seizures consist of coordinated and high-frequency neural activity, our goal was to disrupt neurotransmission with a synaptic tran
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0e7edcddf43428f98301a0fd130e0a60
https://doi.org/10.1534/genetics.115.177600
https://doi.org/10.1534/genetics.115.177600
Autor:
Paul E. Hughes, Daria Timonina, Faria M. Siddiqui, Samantha J. Bilton, Varuna Nangia, Maria Gomez-Caraballo, Aaron N. Hata, Sean Caenepeel, Angela Coxon
Publikováno v:
Cancer Research. 77:2163-2163
There are currently no effective targeted therapeutic strategies for KRAS mutant non-small cell lung cancer (NSCLC). Single agent MEK inhibitors have demonstrated showed disappointing clinical activity, partly due to inability to induce a robust apop
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e1579675d8dc240cbd5a8693df0ea08c
https://doi.org/10.1158/1538-7445.am2017-2163
https://doi.org/10.1158/1538-7445.am2017-2163
Autor:
Sana Raoof, Viveksagar Krishnamurthy Radhakrishna, Lecia V. Sequist, Hillary E. Mulvey, Matthew J. Niederst, Yosef E. Maruvka, Anthony J. Iafrate, Frank Stegmeier, Anthony C. Faber, Fei Ji, Gad Getz, Carlotta Costa, Zofia Piotrowska, Adam S. Crystal, Faria M. Siddiqui, Giulia Siravegna, Elizabeth L. Lockerman, David A. Ruddy, Anuj Kalsy, Leah J. Damon, Hannah L. Archibald, Haichuan Hu, Hyo-eun C. Bhang, Aaron N. Hata, Celina L. Keating, Jeffrey A. Engelman, Alberto Bardelli, Ruslan I. Sadreyev, Maria Gomez-Caraballo, Dana Lee
Although mechanisms of acquired resistance of epidermal growth factor receptor (EGFR)-mutant non-small-cell lung cancers to EGFR inhibitors have been identified, little is known about how resistant clones evolve during drug therapy. Here we observe t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::adbb5c8992e852cbdbb882c6893b2762
http://hdl.handle.net/2318/1613071
http://hdl.handle.net/2318/1613071
Autor:
Maria Gomez-Caraballo, Faria M. Siddiqui, Aaron N. Hata, Yotam Drier, Bradley E. Bernstein, Jeffrey A. Engelman, Lecia V. Sequist
Publikováno v:
Cancer Research. 76:877-877
Acquired drug resistance to targeted cancer therapies remains a significant clinical problem. Although mechanisms of acquired resistance of EGFR mutant non-small cell lung cancers to EGFR inhibitors have been identified, little is known about how res
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::15200015fb589ef9fbb99448ad633d72
https://doi.org/10.1158/1538-7445.am2016-877
https://doi.org/10.1158/1538-7445.am2016-877
Autor:
Lecia V. Sequist, Aaron N. Hata, Hannah L. Archibald, Faria M. Siddiqui, Haichuan Hu, Hillary E. Mulvey, Jeffrey A. Engelman, Matthew J. Niederst, Maria Gomez-Caraballo
Publikováno v:
Molecular Cancer Therapeutics. 14:B53-B53
Despite the success of targeted cancer therapies, acquired drug resistance remains a significant clinical challenge, as in the case of EGFR mutant non-small cell lung cancers (NSCLC) treated with EGFR inhibitor therapy. Although molecular mechanisms
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::95f5d63ff9f529931cc149d09bf866f4
https://doi.org/10.1158/1535-7163.targ-15-b53
https://doi.org/10.1158/1535-7163.targ-15-b53